Peyronies Society Forums

Please login or register.

Login with username, password and session length
Advanced search  

News:

Welcome to Dr. Landon Trost - Directly answering member questions in the "Medical Professionals" section below the Treatment boards. https://www.peyroniesforum.net/index.php/topic,16512.0.html

Pages: [1]   Go Down

Author Topic: Abstracts and presentations from AUA2022  (Read 194 times)

0 Members and 1 Guest are viewing this topic.

HenH

  • Voting Member
  • **
  • Country: nl
  • Offline Offline
  • Gender: Male
  • Posts: 15
Abstracts and presentations from AUA2022
« on: July 19, 2022, 01:55:24 PM »

Yesterday a came across a congress for uroligst in New Orleans, last may. When i looked at the keynotes and discussion panels, I was happy to see there were quite a few peyronie discussions and presentations. See meeting program here:
https://www.auanet.org/annualmeeting/documents/AUA2022/Publications/AUA2022-Meeting-Program-Book.pdf (use find to search for keyword peyronie)

Because it is a lot of information, Please share your thoughts and insights here after reading the study's. Please share and gain some knowledge and understanding together.

PRIAPISM AND PEYRONIE’S DISEASE: WHAT HAVE I LEARNED?
Tom Lue
No paper/presentation/report found (yet)

SEVERITY OF PENILE CURVATURE IN PEYRONIE’S DISEASE DOES NOT CORELATE WITH SHIM OR PDQ SCORES
Thomas Masterson
https://app.swapcard.com/event/2022-aua-annual-meeting-new-orleans/planning/UGxhbm5pbmdfODc5MjM2
In short> For most men curvature alone is not sufficient to define disease severity or bother.

GETTING AHEAD OF THE CURVE—DIAGNOSIS AND TREATMENT FOR PEYRONIE’S DISEASE
Lynn Allmond
No paper/presentation/report found (yet)

IMPROVED PEYRONIE’S DISEASE CURVATURE OUTCOMES USING A MORE AGGRESSIVE COLLAGENASE TECHNIQUE
Alissa Tyler
https://app.swapcard.com/event/2022-aua-annual-meeting-new-orleans/planning/UGxhbm5pbmdfODc5NDE1
In short> Since the FDA approval of Collagenase Clostridium Histolyticum (CCH) for the treatment of Peyronie’s Disease (Peyronies Disease), several investigators have reported outcomes of CCH, with improvements ranging from approximately 15-30%.  More recently, we reported improved results (49% mean improvement) when CCH was combined with RestoreX penile traction therapy (RxPTT). The study tried a more agressife injection and traction control protocol. It has resulted in improved curvature outcomes.

COMPARISON OF COLLAGENASE CLOSTRIDIUM HISTOLYTICUM TO SURGERY FOR THE MANAGEMENT OF PEYRONIE’S
DISEASE: A RANDOMIZED TRIAL
Benjamin Green
https://app.swapcard.com/event/2022-aua-annual-meeting-new-orleans/planning/UGxhbm5pbmdfODc5NDIw
In short > Preliminary 3-month data suggests that when compared to surgery, CCH results in higher overall satisfaction (not statistically significant), decreased curve improvement, improved penile length, and fewer impacts on erectile function and sensation.

INCREMENTAL TREATMENT RESPONSE BY CYCLE WITH COLLAGENASE CLOSTRIDIUM HISTOLYTICUM FOR PEYRONIE’S DISEASE: A POOLED ANALYSIS OF TWO PHASE 3 TRIALS
Matthew Ziegelmann
https://app.swapcard.com/event/2022-aua-annual-meeting-new-orleans/planning/UGxhbm5pbmdfODc5NDIz
In short > The data indicate that incremental benefits were obtained from each of the 4 CCH treatment cycles for Peyronies Disease. Results support clinical benefits with performing a full series of 4 CCH injections, including among nonresponders after initial cycles

EXPLORING ACTINIDIN AS A NOVEL COLLAGENASE TO TREAT HUMAN PEYRONIE’S DISEASE CELLS
Kevin Feng,
https://app.swapcard.com/event/2022-aua-annual-meeting-new-orleans/planning/UGxhbm5pbmdfODc5NDI4
In short > Intralesional injection of Clostridium collagenase histolyticum is no longer available in Canada, thus limiting treatment options. Hayward kiwis are a nutrient dense fruit which contain the soluble protein actinidin. Actinidin has the ability to hydrolyze collagens and fibrinogen and is considered a collagenase alternative.  There have been no studies evaluating the application of actinidin or other novel collagenases on in vitro cellular Peyronies Disease models.  Our study suggests that actinidin may be effective in reducing the amount of collagen in human Peyronies Disease plaques. This novel collagenase could offer future treatment potential.

Please share your thoughts and insights here after reading the study's. Please share and gain some knowledge and understanding togehter.

PATIENT REFERRAL TRENDS AND OUTCOMES OF PENILE PLICATION IN THE CONTEMPORARY ERA: IS XIAFLEX® DRIVING PATIENTS TO SURGERY?
Sam Kusin
https://app.swapcard.com/event/2022-aua-annual-meeting-new-orleans/planning/UGxhbm5pbmdfODc5NDMw
In short > The introduction of CCH for the treatment of Peyronies Disease has led to a significant increase in clinic visits for surgical consultation and PP in patients with previous CCH failure. Post-CCH PP appears to be feasible and safe with overall excellent improvement in curvature.

PEYRONIE’S DISEASE: A FAMILIAL, HERITABLE CONDITION
Michael Christensen
https://app.swapcard.com/event/2022-aua-annual-meeting-new-orleans/planning/UGxhbm5pbmdfODc5NTEy
In short > Peyronie’s Disease (Peyronies Disease) is a superficial fibrosing disorder characterized by inelastic fibrous plaques within the tunica albuginea. Dupuytren’s and Ledderhose disease (DD and LD respectively) are related diseases that affect tissues in the palmar and plantar fascia, respectively. Using a large population database, we previously reported an increased relative risk of disease to relatives of Peyronies Disease probands. We also observed that 75% of Peyronies Disease cases existed within high-risk pedigrees. Both of these findings suggest a genetic component to this disease. Here, we describe the identification of a single high-risk pedigree from which we are identifying genetic variants that may predispose to these disorders.

UNCOVERING THE GENETIC PATHWAYS OF PEYRONIE’S FIBROSIS: SINGLE CELL TRANSCRIPTOMIC ANALYSIS OF
PEYRONIE’S PLAQUE
Luke Witherspoon
https://app.swapcard.com/event/2022-aua-annual-meeting-new-orleans/planning/UGxhbm5pbmdfODc5NTE1
In short > The mechanisms behind the pathogenesis of Peyronie’s disease largely remain a mystery. Single-cell transcriptomics provides a new means to assess the genetic expression profiles occurring on a cell-by-cell basis within a Peyronie’s plaque. This analysis provides insight into the expression profiles of Peyronie’s plaque cell populations stimulated via TGF-beta to activate myofibroblasts akin to the active phase of Peyronie’s disease

OUTCOMES OF PENILE PLICATION IN PEYRONIE’S DISEASE - FUNCTIONAL PENILE LENGTH: “EMPHA-SIZING” WHAT MATTERS
Sarah Christianson
https://app.swapcard.com/event/2022-aua-annual-meeting-new-orleans/planning/UGxhbm5pbmdfODc5NDM2
Surgical procedures for Peyronie’s Disease (Peyronies Disease) are classically categorized as tunical lengthening vs. shortening. Penile plication (PP) reduces penile curvature by placing plication sutures to shorten the convex side of the penis.  While literature regarding PP outcomes demonstrates penile length reduction, there exists no standardization for measurement techniques leading to high inter-study variability. We utilize a novel measurement technique to measure Functional Penile Length (FPL), the length an intimate partner will experience, as a primary surgical outcome.

PATIENTS’ COMPLIANCE WITH SURGERY FOR PEYRONIE DISEASE: A MULTICENTRE EUROPEAN STUDY
Paolo Capogrosso
https://app.swapcard.com/event/2022-aua-annual-meeting-new-orleans/planning/UGxhbm5pbmdfODc5NDM5
Surgery still remains the most effective treatment for Peyronie Disease (Peyronies Disease), despite different conservative therapies have been suggested over time. However, surgical procedures are associated with a non-negligible risk of complications and failures. We investigated patients’ willingness of being operated for Peyronies Disease. Compliance to surgery is low among patients with Peyronies Disease, thus further stressing the urgent need for effective conservative treatments. Surgery should be comprehensively discussed with younger patients with a severe curvature.

POSTOPERATIVE PROGRESS OF MODIFIED GRID INCISION AND SEALING WITH COLLAGEN FLEECE FOR TREATMENT OF PEYRONIE’S DISEASE; CLINICAL AND ULTRASONOGRAPHY OUTCOME
Sun Tae Ahn
https://app.swapcard.com/event/2022-aua-annual-meeting-new-orleans/planning/UGxhbm5pbmdfODc5NTA0

AUXETIC EXPANSION OF THE TUNICA ALBUGINEA FOR PENILE LENGTH AND GIRTH RESTORATION WITHOUT A GRAFT: A CASE SERIES
Alexandre Miranda
https://app.swapcard.com/event/2022-aua-annual-meeting-new-orleans/planning/UGxhbm5pbmdfODc5NTA3
In short > Penile length and girth loss may be caused by many conditions like Peyronie\'s disease, post-radical prostatectomy, erectile dysfunction following ischemic priapism. A new surgical technique has been created to restore penile length and girth loss in patients with severe erectile dysfunction submitted to penile prosthesis implantation (Auxetic technique). The objective of this work is to describe the first use of the new Auxetic technique in seven patients

A DETAILED CHARACTERIZATION OF MEN WITH PEYRONIE’S DISEASE AND NO ASSOCIATED RISK FACTORS
Christian Corsini
https://app.swapcard.com/event/2022-aua-annual-meeting-new-orleans/planning/UGxhbm5pbmdfODc5NTIw
In short > The actual aetiology of Peyronie’s Disease (Peyronies Disease) is still unknown. Although several associated risk factors have been identified (e.g., penile trauma, hypertension, diabetes mellitus, smoking, etc.) some patients develop PDdespite the absence of commonly recognised risk factors. We aimed to investigate the rate of and the clinical characteristics of men with Peyronies Disease and no risk factors versus patients with Peyronies Disease and at least 1 risk factor. Approximately one out of five men presenting for Peyronies Disease had no risk factors or known associated comorbidity. To our knowledge, this is the first study highlighting the clinical characteristics of this subgroup of patients.

STATE-OF-THE-ART LECTURE: SHOCKWAVE THERAPY FOR ERECTILE DYSFUNCTION AND PEYRONIE’S DISEASE:
LEGITIMACY, EFFICACY, AND REGULATORY COMMENTARY
Ranjith Ramasamy
No paper/presentation/report found (yet)

PANEL DISCUSSION: PEYRONIE’S DISEASE MANAGEMENT: TIPS AND TRICKS
No paper/presentation/report found (yet)

SONIC HEDGEHOG SIGNALING IN CORPORA CAVERNOSAL CELLS FROM PROSTATECTOMY, DIABETIC, HYPERTENSION AND PEYRONIE’S PATIENTS WITH ERECTILE DYSFUNCTION
Sarah Martin
https://app.swapcard.com/event/2022-aua-annual-meeting-new-orleans/planning/UGxhbm5pbmdfODc5ODYx
In short > Corpora cavernosa smooth muscle from prostatectomy, diabetic, and Peyronie’s patients increased in response to SHH treatment in a similar manner, suggesting that SHH treatment would be beneficial to enhance smooth muscle regeneration in patients with Erectile Dysfunction of multiple origins.

SEXUALITY UPDATE 2021: CURRENT TRENDS IN THE MANAGEMENT OF ERECTILE DYSFUNCTION, PREMATURE EJACULATION, AND PEYRONIE’S DISEASE
Faysal Yafi
No paper/presentation/report found (yet)

EXTENDED CORPORAL DILATION (ECD) OF MEN WITH PEYRONIE’S DISEASE (Peyronies Disease) AT THE TIME OF INFLATABLE PENILE IMPLANT SURGERY (IPP)
Hisanori Taniguchi
https://app.swapcard.com/event/2022-aua-annual-meeting-new-orleans/planning/UGxhbm5pbmdfODgwNDgw
IN short > Extended corporal dilation results in less residual curvature at the time of IPP and less need for adjuvant maneuvers. This has become our standard approach to dilation in men with Peyronies Disease undergoing IPP surgery

WHAT TREATMENT OPTIONS ARE THERE FOR PEYRONIE’S DISEASE?
Consuelo Conde Redondo
https://app.swapcard.com/event/2022-aua-annual-meeting-new-orleans/planning/UGxhbm5pbmdfODgwNTgw
In short: Non-surgical therapies include the penile extender, The reduction in curvature was enhanced when increasing the usage time. Greater than 6 hours ’use daily resulted in a 36.2 ° reduction compared to baseline (51.4%), whilst less than 4 hours produced a 19.7 ° improvement (28.8%).
Something about xiapex success rate is 34 to 40%
Something about surgery options and aim to shorten surgical times.

SURGICAL TECHNIQUE FOR CONCURRENT PENILE PLICATION AND EXCISION WITH GRAFTING FOR SEVERE PEYRONIE’S DISEASE
Jacob Tannenbaum
https://app.swapcard.com/event/2022-aua-annual-meeting-new-orleans/planning/UGxhbm5pbmdfODgwNTg4
In short > its a video shown during the session.

* most papers are published in The journal of Urology Volume 207 Issue Supplement 5 May 2022
Logged
34 y/o, peyronie since 22 y/o, lump visable mid peniel, slight 20 degree bend upwards, recently pain came back, l, using Pentoxifylline and VED

HenH

  • Voting Member
  • **
  • Country: nl
  • Offline Offline
  • Gender: Male
  • Posts: 15
Re: Abstracts and presentations from AUA2022
« Reply #1 on: July 19, 2022, 02:01:07 PM »

I just started my journey to better understand this disease, so I found the findings of Cristina Corsin (A detailed characteriziation of men with peyronie disease [...]) very interesting to read. I am one of the persons that had no prior risk factors. I find it interesting to read that of 566 patients, 96 (17%) patients did not report any associated comorbidity or risk factor, and none had a positive clinical history for penile trauma.

I find it interesting that she lists the known risk factors such as: diabetes, dyslipidemias, hypertension, ischemic cardiopathy, autoimmune diseases (e.g., Dupuytren’s disease or other connective tissue diseases), previous pelvic surgery (e.g., radical prostatectomy), smoking, alcohol consumption (>1L/week), erectile disfunction (Erectile Dysfunction), and low testosterone levels (< 3 ng/mL). This strengthens my hypothesis that both of my injury’s where caused during periods of high alcohol consumption (as a student, and after a long weekend drinking with friends).

Also interesting that patients with no risk factors had lower age and BMI and had worse degree of curvature.
I don’t understand everything in the paper (like IIEF-EF, RI values, etc), but it was interesting to read.
Logged
34 y/o, peyronie since 22 y/o, lump visable mid peniel, slight 20 degree bend upwards, recently pain came back, l, using Pentoxifylline and VED

Gerald12345

  • Voting Member
  • **
  • Country: de
  • Offline Offline
  • Gender: Male
  • Posts: 42
Re: Abstracts and presentations from AUA2022
« Reply #2 on: July 19, 2022, 02:21:58 PM »

Thanks for sharing, many topics sound interesting!
Logged
Peyronie's onset in 11/2021. Age 37
Two plaques under the glans. Minimal pain, only congenital curvature.
Tadalafil 5 mg per day + arginine and citrulline supplements

Pfract

  • Global Moderator
  • ****
  • Country: ca
  • Offline Offline
  • Gender: Male
  • Posts: 2331
  • #whateverittakes
Re: Abstracts and presentations from AUA2022
« Reply #3 on: July 19, 2022, 11:37:49 PM »

Such a great topic! Thank you for your work!

Bud luck

  • Major Contributor
  • ****
  • Country: us
  • Offline Offline
  • Gender: Male
  • Posts: 736
Re: Abstracts and presentations from AUA2022
« Reply #4 on: July 19, 2022, 11:49:05 PM »

Great information, thank you
Logged
My first symptoms started early in 2019
I tried Traction device, Pentofixiline, Q10, TRT, L-Argenine, cialis
I have narrowing/dent/hinge on the left side of my shaft
My Erectile Dysfunction is getting worse
Had a PRP shot Aug 2021
I have a girlfriend
Age 46

Mikel7

  • Think Tank
  • **
  • Country: us
  • Offline Offline
  • Gender: Male
  • Posts: 1033
Re: Abstracts and presentations from AUA2022
« Reply #5 on: July 20, 2022, 05:51:01 AM »

A lot of info for studying. I was one of the few who was in the low testosterone group and then I developed peyronies.  I can only attribute that to developing peyronies because I had no other issues relating to it's development.
Logged
Lump April 2020, age 61 , Dr Levine 6-26-20,
Dorsal Curve 11-1-20 , Peyronies
Vit E400mg, COQ10, ALCAR, Heat Therapy, Penimaster, Pentox, Cialis, Restorex
had SNHL 7-31-20 - Stopped all Meds because ototoxicity  Heat/traction/VED are working.
Pages: [1]   Go Up
 

Related Topics

  Subject / Started by Replies Last post
0 Replies
5783 Views
Last post May 29, 2006, 12:00:24 PM
by Liam
26 Replies
12593 Views
Last post August 27, 2011, 06:35:06 PM
by newguy
0 Replies
2913 Views
Last post October 04, 2010, 07:57:45 AM
by Tim468